Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
no symptoms reported; Consumer received her second dose of GARDASIL 9 in May of 2025.; This spontaneous report was received from a 26-year-old female patient and refers to herself. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date in August 2023, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) injection, administered for prophylaxis (strength, dose, route, lot #, and expiration date were not reported). On an unknown date in May 2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (Inappropriate schedule of product administration). It was first identified by the patient and pharmacist on 08-Jul-2025. No symptoms were reported (No adverse event). Lot# is being requested and will be submitted if received.